JP2016513663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513663A5 JP2016513663A5 JP2016502244A JP2016502244A JP2016513663A5 JP 2016513663 A5 JP2016513663 A5 JP 2016513663A5 JP 2016502244 A JP2016502244 A JP 2016502244A JP 2016502244 A JP2016502244 A JP 2016502244A JP 2016513663 A5 JP2016513663 A5 JP 2016513663A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 96
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 46
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 229910052731 fluorine Chemical group 0.000 claims description 30
- 239000011737 fluorine Chemical group 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 125000001153 fluoro group Chemical group F* 0.000 claims description 21
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 11
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000008958 Anti-N-Methyl-D-Aspartate Receptor Encephalitis Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000027534 Emotional disease Diseases 0.000 claims description 2
- 206010072378 Encephalitis autoimmune Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 208000032580 NMDA receptor encephalitis Diseases 0.000 claims description 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000006289 Rett Syndrome Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 206010041247 Social fear Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000005298 acute pain Diseases 0.000 claims description 2
- 208000012826 adjustment disease Diseases 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 208000029188 anti-NMDA receptor encephalitis Diseases 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 208000029560 autism spectrum disease Diseases 0.000 claims description 2
- 230000006931 brain damage Effects 0.000 claims description 2
- 231100000874 brain damage Toxicity 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 208000018459 dissociative disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims description 2
- 208000022821 personality disease Diseases 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 230000000698 schizophrenic effect Effects 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 5
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 5
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 2
- 0 C[C@](C*(*)C(*)(*)O)C(CC1)C(C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@](C*(*)C(*)(*)O)C(CC1)C(C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 150000001298 alcohols Chemical group 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779735P | 2013-03-13 | 2013-03-13 | |
| US61/779,735 | 2013-03-13 | ||
| PCT/US2014/026784 WO2014160480A1 (en) | 2013-03-13 | 2014-03-13 | Neuroactive steroids and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017231660A Division JP6530804B2 (ja) | 2013-03-13 | 2017-12-01 | 神経刺激性ステロイドおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513663A JP2016513663A (ja) | 2016-05-16 |
| JP2016513663A5 true JP2016513663A5 (enExample) | 2017-04-13 |
| JP6255082B2 JP6255082B2 (ja) | 2017-12-27 |
Family
ID=51625437
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502244A Active JP6255082B2 (ja) | 2013-03-13 | 2014-03-13 | 神経刺激性ステロイドおよびその使用方法 |
| JP2017231660A Active JP6530804B2 (ja) | 2013-03-13 | 2017-12-01 | 神経刺激性ステロイドおよびその使用方法 |
| JP2019093816A Withdrawn JP2019135261A (ja) | 2013-03-13 | 2019-05-17 | 神経刺激性ステロイドおよびその使用方法 |
| JP2021111379A Active JP7317898B2 (ja) | 2013-03-13 | 2021-07-05 | 神経刺激性ステロイドおよびその使用方法 |
| JP2022159468A Active JP7715692B2 (ja) | 2013-03-13 | 2022-10-03 | 神経刺激性ステロイドおよびその使用方法 |
| JP2025094024A Pending JP2025120299A (ja) | 2013-03-13 | 2025-06-05 | 神経刺激性ステロイドおよびその使用方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017231660A Active JP6530804B2 (ja) | 2013-03-13 | 2017-12-01 | 神経刺激性ステロイドおよびその使用方法 |
| JP2019093816A Withdrawn JP2019135261A (ja) | 2013-03-13 | 2019-05-17 | 神経刺激性ステロイドおよびその使用方法 |
| JP2021111379A Active JP7317898B2 (ja) | 2013-03-13 | 2021-07-05 | 神経刺激性ステロイドおよびその使用方法 |
| JP2022159468A Active JP7715692B2 (ja) | 2013-03-13 | 2022-10-03 | 神経刺激性ステロイドおよびその使用方法 |
| JP2025094024A Pending JP2025120299A (ja) | 2013-03-13 | 2025-06-05 | 神経刺激性ステロイドおよびその使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US20160031930A1 (enExample) |
| EP (4) | EP3461834B1 (enExample) |
| JP (6) | JP6255082B2 (enExample) |
| CN (3) | CN118702755A (enExample) |
| AU (5) | AU2014243773B2 (enExample) |
| BR (1) | BR112015022174B1 (enExample) |
| CA (2) | CA2905359C (enExample) |
| CY (2) | CY1120934T1 (enExample) |
| DK (3) | DK3932932T3 (enExample) |
| ES (3) | ES3042115T3 (enExample) |
| FI (1) | FI3932932T3 (enExample) |
| HR (3) | HRP20251221T1 (enExample) |
| HU (2) | HUE055668T2 (enExample) |
| IL (3) | IL318314A (enExample) |
| LT (3) | LT2968369T (enExample) |
| MX (2) | MX362544B (enExample) |
| PL (3) | PL3461834T3 (enExample) |
| PT (3) | PT2968369T (enExample) |
| RS (3) | RS58166B1 (enExample) |
| RU (1) | RU2684103C2 (enExample) |
| SI (3) | SI2968369T1 (enExample) |
| SM (3) | SMT202500336T1 (enExample) |
| TR (1) | TR201817995T4 (enExample) |
| WO (1) | WO2014160480A1 (enExample) |
| ZA (1) | ZA201506729B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007062266A2 (en) | 2005-11-28 | 2007-05-31 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
| EP2633621B1 (en) | 2010-10-27 | 2017-08-30 | Merus Audio ApS | Audio amplifier using multi-level pulse width modulation |
| PT2753632T (pt) | 2011-09-08 | 2023-08-17 | Sage Therapeutics Inc | Esteróides neuroactivos, composições e respectivas utilizações |
| SMT202500336T1 (it) | 2013-03-13 | 2025-11-10 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2016007762A1 (en) | 2014-07-09 | 2016-01-14 | Duke University | Compositions and methods for the repair of myelin |
| CN112121171A (zh) | 2014-10-07 | 2020-12-25 | 萨奇治疗股份有限公司 | 神经活性化合物及其使用方法 |
| JP6882996B2 (ja) * | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| AU2016289971C1 (en) * | 2015-07-06 | 2022-12-08 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN113292623A (zh) * | 2015-07-06 | 2021-08-24 | 萨奇治疗股份有限公司 | 孕甾醇及其使用方法 |
| CN108135838A (zh) | 2015-10-16 | 2018-06-08 | 马瑞纳斯制药公司 | 包含纳米粒的可注射神经类固醇制剂 |
| JP7112331B2 (ja) * | 2016-04-01 | 2022-08-03 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| TWI752976B (zh) * | 2016-07-07 | 2022-01-21 | 美商賽吉醫療公司 | 氧固醇(oxysterol)及其使用方法 |
| CN109715151A (zh) | 2016-08-11 | 2019-05-03 | 奥维德医疗公司 | 用于治疗癫痫性紊乱的方法和组合物 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CA3038900A1 (en) * | 2016-09-30 | 2018-04-05 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as nmda modulators |
| CN115181153A (zh) * | 2016-10-18 | 2022-10-14 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| CN115322238A (zh) | 2016-10-18 | 2022-11-11 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| CN106632565A (zh) * | 2016-11-07 | 2017-05-10 | 湖南科瑞生物制药股份有限公司 | 一种合成胆固醇的新方法 |
| WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
| WO2020260558A1 (en) | 2019-06-27 | 2020-12-30 | Phenex Pharmaceuticals Ag | 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases |
| CN114728012A (zh) | 2019-08-05 | 2022-07-08 | 马瑞纳斯制药公司 | 用于治疗癫痫持续状态的加奈索酮 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| MX2022006014A (es) | 2019-12-06 | 2022-06-22 | Marinus Pharmaceuticals Inc | Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa. |
| IL308273A (en) * | 2021-05-04 | 2024-01-01 | Sage Therapeutics Inc | Neuroactive steroids for the treatment of mild cognitive impairment associated with Parkinson's disease |
| WO2022261510A1 (en) | 2021-06-11 | 2022-12-15 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
| JP2024532273A (ja) * | 2021-08-25 | 2024-09-05 | セージ セラピューティクス， インコーポレイテッド | ポジティブｎｍｄａモジュレート化合物及びその使用方法 |
| WO2023049295A1 (en) * | 2021-09-22 | 2023-03-30 | Sage Therapeutics, Inc. | Deuterated positive nmda-modulating compounds and methods of use thereof |
| WO2023083979A1 (en) * | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
| JP2024544777A (ja) * | 2021-12-13 | 2024-12-04 | セージ セラピューティクス， インコーポレイテッド | ハンチントン病の治療のための神経活性ステロイド |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| CN114478672B (zh) * | 2022-01-27 | 2024-06-14 | 浙江仙居君业药业有限公司 | 一种he3286的合成方法 |
| CN119677761A (zh) | 2022-06-24 | 2025-03-21 | 萨奇治疗股份有限公司 | 神经活性类固醇的结晶形式 |
| IL318308A (en) | 2022-07-12 | 2025-03-01 | Sage Therapeutics Inc | Crystalline form of a neuroactive steroid |
| TW202508603A (zh) | 2023-05-02 | 2025-03-01 | 美商賽吉醫療公司 | 神經活性類固醇調配物及其使用方法 |
| WO2025227053A1 (en) * | 2024-04-25 | 2025-10-30 | Sage Therapeutics, Inc. | Nmda receptor positive allosteric modulatory compositions and methods of use thereof |
Family Cites Families (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US2673206A (en) | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (enExample) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| US4183852A (en) * | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4174345A (en) | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
| US4269777A (en) | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| JPS6253960A (ja) | 1985-05-30 | 1987-03-09 | Taisho Pharmaceut Co Ltd | ビタミンｄ↓３の誘導体 |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DE4338316A1 (de) | 1993-11-10 | 1995-05-11 | Jenapharm Gmbh | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| EP1038880B1 (en) * | 1994-02-14 | 2007-10-17 | Euro-Celtique S.A. | Androstanes and pregnanes for allosteric modulation of GABA receptor |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| NZ298567A (en) | 1994-11-23 | 2000-01-28 | Cocensys Inc | Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment |
| JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| EP0837874B1 (en) | 1995-06-06 | 2004-12-15 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| US5792635A (en) * | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| RU2182909C2 (ru) | 1995-06-23 | 2002-05-27 | Ново Нордиск А/С | Стероиды, способ регулирования мейоза |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| WO1997003677A1 (en) | 1995-07-24 | 1997-02-06 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| WO1997042215A1 (en) | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| CA2331299A1 (en) | 1998-05-11 | 1999-11-18 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| ATE256144T1 (de) | 1998-05-13 | 2003-12-15 | Novo Nordisk As | Verwendung von verbindungen mit der fähigkeit die meiose zu regulieren |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1111167C (zh) | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途 |
| CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) * | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| CA2446314C (en) * | 2001-05-03 | 2011-02-22 | The University Of Chicago | Liver x receptor agonists |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| JP2005508368A (ja) | 2001-11-08 | 2005-03-31 | ザ ユニバーシティー オブ シカゴ | 高コレステロール濃度に関連した疾患の治療方法 |
| AU2002360489A1 (en) | 2001-12-07 | 2003-06-23 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
| PL213697B1 (pl) | 2002-03-27 | 2013-04-30 | Phytopharm Plc | Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych |
| KR101130212B1 (ko) | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| WO2004055201A2 (en) | 2002-12-13 | 2004-07-01 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| US20050142192A1 (en) | 2003-10-15 | 2005-06-30 | Wyeth | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| US8604011B2 (en) | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20070032464A1 (en) * | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| KR101358078B1 (ko) | 2004-11-01 | 2014-02-06 | 주식회사 유스팜인터내셔널 | 근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물 |
| CA2643732C (en) | 2006-02-27 | 2012-08-21 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| CN101164540A (zh) | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| WO2008057468A1 (en) | 2006-11-02 | 2008-05-15 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| WO2008063128A1 (en) | 2006-11-21 | 2008-05-29 | Umecrine Ab | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
| CN104892498A (zh) | 2007-06-20 | 2015-09-09 | 奥斯拜客斯制药有限公司 | 作为纤维化抑制剂的取代的n-芳基吡啶酮 |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| WO2009059239A2 (en) | 2007-11-02 | 2009-05-07 | Mayo Foundation For Medical Education And Research | REDUCING Aβ42 LEVELS AND Aβ AGGREGATION |
| CA2703497A1 (en) | 2007-11-06 | 2009-05-14 | N.V. Organon | A method of hormone suppression in humans |
| JP2011505357A (ja) | 2007-12-03 | 2011-02-24 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | ヘッジホッグシグナル伝達、骨誘導、抗脂肪生成、及びｗｎｔシグナル伝達を活性するためのオキシステロール |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| EP2244577B1 (en) | 2008-01-25 | 2012-10-31 | Merck Sharp & Dohme Corp. | Quinolizidinone m1 receptor positive allosteric modulators |
| EP2255818B1 (en) | 2008-02-19 | 2018-08-22 | Earnest Medicine Co., Ltd. | Oral or enteral composition useful for recovery of physical functions |
| SG195568A1 (en) | 2008-05-09 | 2013-12-30 | Univ Emory | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| CN101683348B (zh) * | 2008-09-23 | 2012-07-04 | 中山大学 | 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用 |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
| WO2010088408A2 (en) | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor antagonists for the treatment of neurological conditions |
| JP2013500986A (ja) | 2009-07-29 | 2013-01-10 | ザ・ユニバーシティ・オブ・シカゴ | 肝臓ｘ受容体アゴニスト |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| JP2013521307A (ja) * | 2010-03-03 | 2013-06-10 | サトリ・ファーマシューティカルズ・インコーポレイテッド | 神経変性障害を治療するのに有用な化合物 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| WO2012142039A1 (en) | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| US20140335050A1 (en) | 2011-05-27 | 2014-11-13 | The General Hospital Corporation | Methods, compositions, and kits for the treatment of cancer |
| WO2013019711A2 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| PT2753632T (pt) | 2011-09-08 | 2023-08-17 | Sage Therapeutics Inc | Esteróides neuroactivos, composições e respectivas utilizações |
| PT2763979T (pt) | 2011-10-07 | 2019-04-12 | Takeda Pharmaceuticals Co | Compostos de 1-arilcarbonil-4-oxi-piperidina úteis para o tratamento de doenças neurodegenerativas |
| EP2766380B1 (en) | 2011-10-14 | 2019-04-24 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| EP2841067A4 (en) | 2012-04-25 | 2016-04-13 | Univ California | MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME |
| US9737522B2 (en) | 2012-08-09 | 2017-08-22 | Emory University | NMDA receptor modulators and uses related thereto |
| US20140149272A1 (en) | 2012-08-17 | 2014-05-29 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| SG11201504848QA (en) | 2012-12-18 | 2015-07-30 | Univ Washington | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same |
| CN112552364A (zh) | 2013-01-23 | 2021-03-26 | 司菲埃拉制药私人有限公司 | 用于线粒体生物发生和与线粒体功能障碍或耗竭相关的疾病的新颖11β-羟基类固醇化合物 |
| MX2015009773A (es) | 2013-01-29 | 2016-08-05 | Aptinyx Inc | Moduladores de receptores nmda de espiro-lactama y sus usos. |
| CN112057457A (zh) | 2013-03-13 | 2020-12-11 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| SMT202500336T1 (it) | 2013-03-13 | 2025-11-10 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| RU2019126333A (ru) | 2013-04-17 | 2019-10-08 | Сейдж Терапьютикс, Инк. | 19-нор нейроактивные стероиды и способы их применения |
| CN106456729A (zh) | 2014-02-08 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 治疗阿尔茨海默氏病的方法 |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2016007762A1 (en) | 2014-07-09 | 2016-01-14 | Duke University | Compositions and methods for the repair of myelin |
| CN112121171A (zh) | 2014-10-07 | 2020-12-25 | 萨奇治疗股份有限公司 | 神经活性化合物及其使用方法 |
| AU2016289971C1 (en) | 2015-07-06 | 2022-12-08 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN113292623A (zh) | 2015-07-06 | 2021-08-24 | 萨奇治疗股份有限公司 | 孕甾醇及其使用方法 |
| JP6882996B2 (ja) | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| JP7112331B2 (ja) | 2016-04-01 | 2022-08-03 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| TWI752976B (zh) | 2016-07-07 | 2022-01-21 | 美商賽吉醫療公司 | 氧固醇(oxysterol)及其使用方法 |
| EP3481844B1 (en) | 2016-07-11 | 2024-04-17 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| CA3038900A1 (en) | 2016-09-30 | 2018-04-05 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as nmda modulators |
| CN115181153A (zh) | 2016-10-18 | 2022-10-14 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| CN115322238A (zh) | 2016-10-18 | 2022-11-11 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| AU2018288883B2 (en) | 2017-06-23 | 2022-06-02 | Intercept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of bile acid derivatives |
| WO2019094724A1 (en) | 2017-11-10 | 2019-05-16 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
-
2014
- 2014-03-13 SM SM20250336T patent/SMT202500336T1/it unknown
- 2014-03-13 CA CA2905359A patent/CA2905359C/en active Active
- 2014-03-13 SM SM20180657T patent/SMT201800657T1/it unknown
- 2014-03-13 EP EP18190034.1A patent/EP3461834B1/en active Active
- 2014-03-13 CN CN202410694955.5A patent/CN118702755A/zh active Pending
- 2014-03-13 IL IL318314A patent/IL318314A/en unknown
- 2014-03-13 BR BR112015022174-2A patent/BR112015022174B1/pt active IP Right Grant
- 2014-03-13 WO PCT/US2014/026784 patent/WO2014160480A1/en not_active Ceased
- 2014-03-13 SI SI201430981T patent/SI2968369T1/sl unknown
- 2014-03-13 ES ES21172859T patent/ES3042115T3/es active Active
- 2014-03-13 SI SI201431866T patent/SI3461834T1/sl unknown
- 2014-03-13 FI FIEP21172859.7T patent/FI3932932T3/fi active
- 2014-03-13 PL PL18190034T patent/PL3461834T3/pl unknown
- 2014-03-13 PL PL21172859.7T patent/PL3932932T3/pl unknown
- 2014-03-13 CA CA3114062A patent/CA3114062A1/en not_active Abandoned
- 2014-03-13 EP EP21172859.7A patent/EP3932932B8/en active Active
- 2014-03-13 DK DK21172859.7T patent/DK3932932T3/da active
- 2014-03-13 DK DK14774060.9T patent/DK2968369T3/en active
- 2014-03-13 LT LTEP14774060.9T patent/LT2968369T/lt unknown
- 2014-03-13 CN CN201480026165.4A patent/CN105246486B/zh active Active
- 2014-03-13 LT LTEP21172859.7T patent/LT3932932T/lt unknown
- 2014-03-13 EP EP14774060.9A patent/EP2968369B1/en active Active
- 2014-03-13 RU RU2015143466A patent/RU2684103C2/ru active
- 2014-03-13 TR TR2018/17995T patent/TR201817995T4/en unknown
- 2014-03-13 HU HUE18190034A patent/HUE055668T2/hu unknown
- 2014-03-13 LT LTEP18190034.1T patent/LT3461834T/lt unknown
- 2014-03-13 HU HUE21172859A patent/HUE072324T2/hu unknown
- 2014-03-13 DK DK18190034.1T patent/DK3461834T3/da active
- 2014-03-13 PT PT14774060T patent/PT2968369T/pt unknown
- 2014-03-13 HR HRP20251221TT patent/HRP20251221T1/hr unknown
- 2014-03-13 AU AU2014243773A patent/AU2014243773B2/en active Active
- 2014-03-13 SI SI201432115T patent/SI3932932T1/sl unknown
- 2014-03-13 EP EP25189422.6A patent/EP4643945A3/en active Pending
- 2014-03-13 JP JP2016502244A patent/JP6255082B2/ja active Active
- 2014-03-13 RS RS20181442A patent/RS58166B1/sr unknown
- 2014-03-13 SM SM20210475T patent/SMT202100475T1/it unknown
- 2014-03-13 MX MX2015012430A patent/MX362544B/es active IP Right Grant
- 2014-03-13 RS RS20211011A patent/RS62235B1/sr unknown
- 2014-03-13 US US14/775,678 patent/US20160031930A1/en not_active Abandoned
- 2014-03-13 CN CN202011101409.4A patent/CN112375115A/zh active Pending
- 2014-03-13 PT PT181900341T patent/PT3461834T/pt unknown
- 2014-03-13 PL PL14774060T patent/PL2968369T3/pl unknown
- 2014-03-13 IL IL280068A patent/IL280068B2/en unknown
- 2014-03-13 PT PT211728597T patent/PT3932932T/pt unknown
- 2014-03-13 MX MX2019000995A patent/MX388210B/es unknown
- 2014-03-13 RS RS20250988A patent/RS67266B1/sr unknown
- 2014-03-13 ES ES14774060T patent/ES2699445T3/es active Active
- 2014-03-13 ES ES18190034T patent/ES2886506T3/es active Active
- 2014-03-13 HR HRP20181994TT patent/HRP20181994T1/hr unknown
-
2015
- 2015-09-08 IL IL241301A patent/IL241301B/en active IP Right Grant
- 2015-09-10 ZA ZA2015/06729A patent/ZA201506729B/en unknown
-
2017
- 2017-05-05 US US15/588,305 patent/US20170305960A1/en not_active Abandoned
- 2017-12-01 JP JP2017231660A patent/JP6530804B2/ja active Active
-
2018
- 2018-03-09 US US15/917,263 patent/US10227375B2/en active Active
- 2018-11-27 CY CY181101258T patent/CY1120934T1/el unknown
- 2018-12-20 US US16/227,013 patent/US11104701B2/en active Active
-
2019
- 2019-02-22 AU AU2019201275A patent/AU2019201275B2/en active Active
- 2019-05-17 JP JP2019093816A patent/JP2019135261A/ja not_active Withdrawn
-
2021
- 2021-01-14 AU AU2021200205A patent/AU2021200205B2/en active Active
- 2021-07-05 JP JP2021111379A patent/JP7317898B2/ja active Active
- 2021-07-21 US US17/381,829 patent/US11905309B2/en active Active
- 2021-08-10 CY CY20211100713T patent/CY1124629T1/el unknown
- 2021-08-12 HR HRP20211300TT patent/HRP20211300T1/hr unknown
-
2022
- 2022-10-03 JP JP2022159468A patent/JP7715692B2/ja active Active
- 2022-11-28 AU AU2022279366A patent/AU2022279366B2/en active Active
-
2024
- 2024-01-05 US US18/405,657 patent/US20240287125A1/en active Pending
-
2025
- 2025-04-29 AU AU2025203021A patent/AU2025203021A1/en active Pending
- 2025-06-05 JP JP2025094024A patent/JP2025120299A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513663A5 (enExample) | ||
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| RU2470011C2 (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| JP2017531020A5 (enExample) | ||
| JP2018505898A5 (enExample) | ||
| JP2019519587A5 (enExample) | ||
| JP2013010792A5 (enExample) | ||
| JP2014526469A5 (enExample) | ||
| JP2012521994A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| JP2016518437A5 (enExample) | ||
| JP2014051526A5 (enExample) | ||
| JP2017518323A5 (enExample) | ||
| JP2015514060A5 (enExample) | ||
| JP2018519351A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| JP2016513130A5 (enExample) | ||
| JP2018519329A5 (enExample) | ||
| JP2013502431A5 (enExample) | ||
| JP2014528485A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2017531019A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| JP2013502430A5 (enExample) |